Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Chief Financial Officer and Vice President of Business Development
Vice President of Research & Development
Consulting Medical Director and Member of Clinical Advisory Board
Director of Regulatory Compliance
Compensation as of Fiscal Year 2014.
Altor BioScience Corporation Key Developments
Altor Bioscience Corporation Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma
Nov 4 14
Altor BioScience Corporation announced that it has enrolled patients with relapsed or refractory multiple myeloma (MM) in a clinical trial using its IL-15-based immunostimulatory complex ALT-803. This study is supported by a Small Business Innovation Research (SBIR) Phase II grant recently awarded to Altor by the National Cancer Institute (NCI). The MM trial represents the fourth clinical trial in the United States (U.S.) launched by Altor for the ALT-803 superagonist complex in the fight against cancer. As the second most common blood cancer, MM is a cancer of the plasma cells involved in producing antibodies, causing cancer cells to accumulate in the bone marrow and crowding out normal blood cells from fighting off infection. ALT-803 is considered one of the most promising novel immunotherapeutic agents by NCI for cancer treatment. In preclinical studies, ALT-803 potently activates immune cells to defend against disease, simultaneously mobilizing both the innate and adaptive arms of the immune system to elicit rapid and long-lasting anti-tumor responses. Encouraging preclinical studies of ALT-803 in MM led to the development of the ALT-803 clinical study in patients with relapsed or refractory MM. According to NCI, there will be an estimated 24,050 new cases of MM and 11,090 deaths due to MM in the U.S. in 2014. MM is a disease of the elderly with a median age at diagnosis of 69 years. The number of MM patients is expected to increase over time due to the increasing life expectancy of the normal population. Unfortunately, even with the development of novel therapies recently approved by the U.S. Food and Drug Administration (FDA), MM remains an incurable disease and many patients with the disease will eventually relapse. Therefore, Altor's strategy for ALT-803 is to fulfill the needs of this segment of the market and complement or improve the efficacy of currently available therapies.
Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM
Oct 11 14
Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Warren Marcus, Scientist and Business Development Associate.
Altor BioScience Corporation and Shenzhen Beike Biotechnology Co., Ltd Announce License Agreement for Immunotherapeutic ALT-803 in China
Sep 10 14
Altor BioScience Corporation and Shenzhen Beike Biotechnology Co. Ltd. (Beike), announced that they have entered into a license agreement to develop and commercialize ALT-803, Altor's proprietary Interleukin-15 (IL-15) based superagonist complex, in China. Under the terms of the agreement, Altor has granted Beike an exclusive license for the research, development, manufacture and commercialization of ALT-803 for therapeutic uses in all human disease indications in China. As part of the agreement, Altor will receive an up-front fee of USD 4 million and could potentially receive over USD 200 million in development and sales milestones, and tiered double-digit royalties based on sales of licensed products. Beike has also made a strategic equity investment of approximately USD 5 million into Altor. Beike will have marketing rights for licensed products in China, and Altor will retain marketing rights in all other countries.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 10, 2014